Cytoreductive Surgery (CRS) and HIPEC for Advanced Ovarian Cancer with Peritoneal Metastases: Italian PSM Oncoteam Evidence and Study Purposes.

Abstract

Ovarian cancer is the eighth most common neoplasm in women with a high mortality rate mainly due to a marked propensity for peritoneal spread directly at diagnosis, as well as tumor recurrence after radical surgical treatment. Treatments for peritoneal metastases have to be designed from a patient's perspective and focus on meaningful measures of benefit. Hyperthermic intraperitoneal chemotherapy (HIPEC), a strategy combining maximal cytoreductive surgery with regional chemotherapy, has been proposed to treat advanced ovarian cancer. Preliminary results to date have shown promising results, with improved survival outcomes and tumor regression. As knowledge about the disease process increases, practice guidelines will continue to evolve. In this review, we have reported a broad overview of advanced ovarian cancer management, and an update of the current evidence. The future perspectives of the Italian Society of Surgical Oncology (SICO) are discussed conclusively.

• Authors: Daniele Marrelli, Luca Ansaloni, Orietta Federici, Salvatore Asero, Ludovico Carbone, Luigi Marano, Gianluca Baiocchi, Marco Vaira, Federico Coccolini, Andrea Di Giorgio, Massimo Framarini, Roberta Gelmini, Carmen Palopoli, Fabio Accarpio, Anna Fagotti
• Journal: Cancers (Cancers (Basel)) Vol. 14 Issue 23 (Dec 06 2022) ISSN: 2072-6694 [Print] Switzerland
• PMID: 36497490 (Publication Type: Journal Article, Review)